(P1016) |
Proarrhythmic Effect of Steroid Therapy in Cardiac Sarcoidosis |
|
D. Dechering, A. Bittner, J. Köbe, K. Wasmer, S. Kochhäuser, S. Zellerhoff, G. Mönnig, L. Eckardt (Münster) |
(P1017) |
Herzinsuffizienz bei Noncompaction Kardiomyopathie: Daten des Deutschen-Noncompaction-Registers (ALKK) |
|
B. J. Gerecke, C. Stöllberger, W. Fehske, B. Schneider, D. Nothnagel, R. Engberding (Wolfsburg, Köln, Lübeck, Ludwigsburg; Wien, AT) |
(P1018) |
Untersuchungen zur kardioprotektiven Wirkung von Endothelinantagonisten unter Doxorubicingabe. |
|
M. Schwebe, S. Bien, S. Schlensak, A. Poesch, H. K. Kroemer (Greifswald) |
(P1019) |
Comprehensive Assessment of Long Term Enzyme Replacement Therapy on Fabry Disease – The 5 Year Data |
|
K. Baumgärtner, M. Niemann, A. Emmert, F. Breunig, J. Strotmann, M. Beer, C. Sommer, G. Ertl, C. Wanner, F. Weidemann (Würzburg, Kiel) |
(P1020) |
Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) using Polyvinyl Alcohol Foam particles in the treatment of Hypertrophic Obstructive Cardiomyopathy: A single center experience |
|
M. Roser, A. Sander, E. Wellnhofer, S. Dreysse, E. Fleck (Berlin) |
(P1021) |
Molecular effects of the amino acid exchanges R20C and K206Q of cardiac Troponin I, linked to familial hypertrophic cardiomyopathy (FHC) |
|
M. Saes, D. Kindsvater, I. Morano, A. Mügge, K. Jaquet (Bochum, Berlin) |
(P1022) |
Doxorubicin induced Cardiomyopathy: Influence of oxysteroles and the cholesterol transporters ABCA1 and ABCG1 |
|
M. Grube, T. Budde, H. E. Meyer zu Schwabedissen, M. Schwebe, S. Bien, D. Lütjohann, H. K. Kroemer (Greifswald, Bonn) |
(P1023) |
Effects of enzyme replacement therapy with agalsidase in patients with Fabry’s disease on cardiac mass and function: an analysis of the Fabry-Münster-Study (FaMüS) data |
|
M. A. Engelen, T. B. Baumeister, E. von dem Bussche, J. Rosmus, F. Landeta, K. Tiemann, T. Marquardt, T. Duning, N. Osada, E. Brand, R. M. Schäfer, J. Stypmann (Münster) |
(P1024) |
Different application protocols of cardioprotective cyclic peptides yield similar therapeutic efficacies in beta1-receptor antibody-induced cardiomyopathy. |
|
V. Boivin, A. Schlipp, C. Zechmeister, N. Deubner, D. Berliner, G. Ertl, M. Lohse, R. Jahns (Würzburg) |
(P1025) |
Fully functional membrane beta1-adrenoceptors with single amino-acid mutations in the second extracellular loop are not recognized by conformational anti-beta1-receptor antibodies. |
|
M. Sättele, A. Schlipp, J. Ullrich, M. Lohse, R. Jahns, V. Boivin (Würzburg) |
(P1026) |
Cardiac OCTN2: Expression in dilated cardiomyopathy and impact on cardiac function |
|
K. Bonitz, M. Schwebe, S. Heinrich, S. Ameling, G. Jedlitschky, U. Völker, S. B. Felix, M. Grube, H. K. Kroemer (Greifswald) |
(P1027) |
Eosinophilic myocarditis mimicking a midventricular Tako-Tsubo cardiomyopathy |
|
H. Jansen, K. Mortensen, P. Linsel-Nitschke, W. Lieb, H. Schunkert, M. Reppel (Lübeck) |
(P1028) |
Impact of pericardectomy on long- and short-term outcome in patients with chronic constrictive pericaritis |
|
C. Mattusch, U. M. Müller, A. Linke, G. C. Schuler (Leipzig) |
(P1029) |
Pathogenetic role and diagnostic value of vascular endothelial growth factor in malignant pericardial effusion |
|
K. Karatolios, S. Pankuweit, A. Richter, R. Moosdorf, B. Maisch (Marburg) |